The understanding of the pathways disrupted and the nature of the proteins influenced by FMRP, and their implications on the clinical phenotypes and other neuropsychological functions is important since current interventions for FXS are mainly supportive, with curative ones under development. The gene discussed is FMR1; the disease is fragile X syndrome.